Scarica l'app Stockscreener
11.63
0.69%
0.08
Dopo l'orario di chiusura:
11.22
-0.41
-3.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
Using R and stats models for EyePoint Pharmaceuticals Inc. forecasting2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
EyePoint announces proposed public offering of common stock - MSN
EyePoint Pharmaceuticals Raises $141M in Public Offering - TipRanks
[8-K] EyePoint Pharmaceuticals, Inc. Reports Material Event | EYPT SEC FilingForm 8-K - Stock Titan
What does recent volatility data suggest for EyePoint Pharmaceuticals Inc.IPO Watch & Community Driven Trade Alerts - newser.com
EyePoint (EYPT) Grants Stock Options to New Employees - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
13,500-Share Grant: EyePoint Issues Stock Options at $11.73 Exercise Price, Vesting 4 Years - Stock Titan
EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target - Seeking Alpha
EyePoint Pharmaceuticals Sets Pricing of Its Public Stock Offering - VisionMonday.com
EyePoint Pharmaceuticals, Inc.Common Stock (NQ: EYPT - FinancialContent
Is EyePoint Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study - inkl
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Chart based analysis of EyePoint Pharmaceuticals Inc. trends2025 Trading Recap & Real-Time Chart Breakout Alerts - newser.com
EyePoint Pharma falls on pricing $150 mln stock offering - TradingView
EYPT Sets Pricing Range for Recent Offering - GuruFocus
EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU™ Phase 3 clinical programs - MSN
EyePoint Pharmaceuticals prices $150 million public offering By Investing.com - Investing.com Nigeria
EyePoint Announces Pricing of Public Offering - The Manila Times
Eyepoint Pharmaceuticals Prices Public Offering Of 11 Million Shares At $12.00 Per Share - TradingView
$150M Offering: EyePoint Prices 11M Shares to Advance DURAVYU Trials and Support Pipeline - Stock Titan
Eyepoint Pharmaceuticals prices public offering of 11 million shares at $12.00 per share - MarketScreener
EyePoint’s DURAVYU advances to phase 3 trials for diabetic eye disease - Investing.com Canada
EyePoint Pharmaceuticals IncAnnounces $150 Mln Public Offering of Common Stock - 富途牛牛
EyePoint Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com Nigeria
JPMorgan and Partners Manage Offering for EYPT - GuruFocus
EyePoint (EYPT) Launches $150 Million Public Share Offering - GuruFocus
EYPT launches $150M raise; cash runway projected into Q4 2027 - Stock Titan
EyePoint Pharmaceuticals (EYPT) Announces $150 Million Public Of - GuruFocus
EyePoint Pharmaceuticals Initiates Phase 3 Program for Duravyu to Treat Diabetic Macular Edema - MarketScreener
EyePoint Pharma slips after announcing $150 mln stock offering - TradingView
EyePoint Announces Proposed Public Offering of Common Stock - The Manila Times
EyePoint Pharmaceuticals launches $150 million public offering - Investing.com
Eyepoint Pharmaceuticals stock falls after $150 million share offering By Investing.com - Investing.com Australia
Eyepoint Pharmaceuticals stock falls after $150 million share offering - Investing.com
EyePoint’s DURAVYU advances to phase 3 trials for diabetic eye disease By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program - TipRanks
Eyepoint Pharmaceuticals Inc files for mixed shelf size not disclosedSEC filing - MarketScreener
$150M Offering: EyePoint Launches Public Offering of Common Stock with $22.5M Underwriters' Option - Stock Titan
EyePoint (EYPT) Advances Duravyu Phase 3 Program for Diabetic Ma - GuruFocus
Eyepoint Pharmaceuticals announces Phase 3 diabetes program starting in 2026 - Traders Union
Eyepoint Pharmaceuticals announces phase 3 program initiation for Duravy in diabetic macular edema - MarketScreener
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema - The Manila Times
EyePoint Pharmaceuticals Advances DURAVYU to Phase 3 Trials for Diabetic Macular Edema and Wet AMD, First Patient Dosing Expected in Q1 2026 - Quiver Quantitative
EYPT posts investor deck with preliminary 9/30/2025 cash; Phase 3 slated - Stock Titan
EyePoint Pharmaceuticals, Inc. Announces Pivotal Phase 3 Program Initiation for Duravuyu in Diabetic Macular Edema - MarketScreener
Will EyePoint Pharmaceuticals Inc. stock split attract more investorsJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Will earnings trigger a reversal in EyePoint Pharmaceuticals Inc.Rate Hike & Precise Swing Trade Entry Alerts - newser.com
[8-K] – EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102) | EYPT SEC FilingForm 8-K - Stock Titan
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):